Reviewing Athersys (NASDAQ:ATHX) and Revelation Biosciences (NASDAQ:REVB)

Athersys (NASDAQ:ATHX) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Profitability

This table compares Athersys and Revelation Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Athersys	N/A	N/A	-223.03%
Revelation Biosciences	N/A	-152.41%	-74.43%

Valuation & Earnings

This table compares Athersys and Revelation Biosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A
Revelation Biosciences	N/A	N/A	-$120,000.00	($28.53)	-0.03

Revelation Biosciences has lower revenue, but higher earnings than Athersys. Revelation Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Athersys has a beta of -0.9, indicating that its stock price is 190% less volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Athersys and Revelation Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athersys	0	0	0	0	N/A
Revelation Biosciences	0	0	0	0	N/A

Insider & Institutional Ownership

19.4% of Athersys shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 0.0% of Athersys shares are held by company insiders. Comparatively, 0.2% of Revelation Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

About Revelation Biosciences

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.